1.Solitary spleen metastasis of endometrial carcinoma: a case report.
Chinese Journal of Cancer 2010;29(1):30-31
Adenocarcinoma
;
drug therapy
;
pathology
;
secondary
;
surgery
;
Chemotherapy, Adjuvant
;
Endometrial Neoplasms
;
drug therapy
;
pathology
;
surgery
;
Female
;
Humans
;
Hysterectomy
;
Middle Aged
;
Splenectomy
;
Splenic Neoplasms
;
drug therapy
;
pathology
;
secondary
;
surgery
3.Clinical analysis of 215 elderly patients with cervical cancer.
Min CHENG ; Ling-ying WU ; Wen-hua ZHANG ; Man-ni HUANG ; Rong ZHANG
Chinese Journal of Oncology 2009;31(5):388-391
OBJECTIVETo investigate the clinical features, treatment outcomes and possible prognostic factors in elderly patients with cervical cancer.
METHODSClinical data of 215 elderly women (> or = 65-years-old) with cervical cancer were retrospectively analyzed. Most patients (89.3%) had advanced stage ( II b-IV) disease. Eight of the 215 patients (3.7%) underwent surgical treatment, and six of those received postoperative radiotherapy. 133 patients received radiotherapy alone, and 74 patients underwent concurrent chemotherapy and radiotherapy.
RESULTSThe median follow-up time was 48 months (range: 12-102 months). The overall 5-year survival rate was 63.7%. The 5-year survival rate for stage I, II, III, IV were 83.2%, 76.4%, 39.0% and 0, respectively. There was no significant difference in 5-year survival rate between patients treated with concurrent chemotherapy combined with radiotherapy and radiotherapy alone. In multivariate analysis, lymph node metastasis, advanced stage, non-squamous histologies and poor differentiation were all negative prognostic factors for the overall survival.
CONCLUSIONThe treatment strategy for elderly cervical cancer patients should be individually planned according to the disease stage and performance status of the patients. Usually, one radical therapy modality can be chosen, and combined modality therapy is not suggested.
Adenocarcinoma ; drug therapy ; pathology ; radiotherapy ; surgery ; Adenocarcinoma, Clear Cell ; drug therapy ; pathology ; radiotherapy ; surgery ; Aged ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Squamous Cell ; drug therapy ; pathology ; radiotherapy ; surgery ; Cisplatin ; therapeutic use ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lymphatic Metastasis ; Neoplasm Staging ; Retrospective Studies ; Survival Rate ; Uterine Cervical Neoplasms ; drug therapy ; pathology ; radiotherapy ; surgery ; Young Adult
4.A Case of Synchronous Early Gastric Cancer and Diffuse Large B Cell Lymphoma Treated with Endoscopic Submucosal Dissection and Chemotherapy.
Jae Hyun PARK ; Jae Young JANG ; Yong Duck CHO ; Seok Ho DONG ; Hyo Jong KIM ; Byung Ho KIM ; Young Woon CHANG
The Korean Journal of Gastroenterology 2012;59(5):377-381
Among malignant tumors of the stomach, adenocarcinoma takes up about 95% and the remaining are mostly lymphomas, being less than 5%. The majority of lymphomas are B cell lymphomas, and the most common types are low-grade B cell lymphoma of mucosa-associated lymphoid tissue and diffuse large B cell lymphoma (DLBL). The synchronous occurrence of adenocarcinoma and lymphoma in the stomach is being reported rarely. Especially the concurrence of adenocarcinoma and DLBL is very scarce and less than 10 cases have been reported inside and outside this country. In the past, the general treatment for cases of concurrence of adenocarcinoma and DLBL when surgery is possible according to cancer stages was gastrectomy, followed by single or combined chemotherapy and radiation treatment. However, when considering that most cases of concurrent adenocarcinoma were early gastric cancer which is limited to the mucosa, endoscopic submucosal dissection (ESD) can become an alternative treatment method for gastrectomy. We report the experience with chemotherapy and ESD done together instead of surgery, in patients concurrently diagnosed with early gastric cancer and gastric lymphoma.
Adenocarcinoma/*drug therapy/surgery
;
Anti-Bacterial Agents/therapeutic use
;
Antineoplastic Agents/therapeutic use
;
Drug Therapy, Combination
;
Helicobacter Infections/drug therapy
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology
;
Male
;
Middle Aged
;
Stomach Neoplasms/*drug therapy/surgery
5.Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients.
Hui WU ; Liang WANG ; Yu-long HE ; Jian-bo XU ; Shi-rong CAI ; Jin-ping MA ; Chuang-qi CHEN ; Xin-hua ZHANG ; Wen-hua ZHAN
Chinese Journal of Oncology 2013;35(7):509-513
OBJECTIVETo explore the impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer (EGC) patients.
METHODSA total of 142 EGC cases screened from database of gastric cancer of Sun Yat-sen University, from Aug. 1994 to Jan. 2010, were included in this study. According to the lymph node metastasis status, they were divided into lymph node negative (n = 116) and lymph node positive (n = 26) groups. The clinicopathological features of the two groups and the impact of extent of lymph node dissection on the prognosis were analyzed.
RESULTSThere were no significant differences in age, gender, tumor size and location, Borrmann typing, WHO TNM staging, histological typing, and CEA value between the two groups (P > 0.05). The TNM stages in the lymph node positive group were higher than that in the lymph node negative group (P < 0.001). Between the cases who underwent D1 (n = 21) and D2 (n = 121) dissection, there were no significant differences in postoperative hospital days, blood transfusion volume, and operation time (P > 0.05). The median numbers of LN dissected in D1 and D2 cases were 4 (0 to 16) and 20 (12 to 30), with a significant difference (P = 0.000), but the number of positive LN without significant difference (P = 0.502). The postoperative complication rates were 9.5% in the D1 and 3.3% in the D2 dissection groups, without a significant difference (P = 0.128). The median survival time of the lymph node negative and positive groups was 156 vs. 96 months (P = 0.010). In cases who received D2 and D1 lymph node dissection, the median survival time (MST) was 156 vs. 96 months (P = 0.0022). In the lymph node positive group, D2 dissection prolonged survival time significantly than D1 dissection (96 vs. 27months) (P = 0.001). Cox regression analysis showed that the extent of lymph node dissection and LN metastasis were independent prognostic factors for EGC patients.
CONCLUSIONSIt is not able to accurately assess the LN metastasis status preoperatively according to the routine clinicopathological features. For the patients with unknown LN metastasis status, D2 dissection should be the first choice. Comparing with D1 dissection, the morbidity of D2 dissection are not increased, but survival time is prolonged.
Adenocarcinoma ; drug therapy ; pathology ; surgery ; Adenocarcinoma, Mucinous ; drug therapy ; pathology ; surgery ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Signet Ring Cell ; drug therapy ; pathology ; surgery ; Chemotherapy, Adjuvant ; Female ; Fluorouracil ; administration & dosage ; Follow-Up Studies ; Gastrectomy ; methods ; Humans ; Leucovorin ; administration & dosage ; Lymph Node Excision ; methods ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Proportional Hazards Models ; Retrospective Studies ; Stomach Neoplasms ; drug therapy ; pathology ; surgery ; Survival Rate
6.Advance in pulmonary adenocarcinoma with micropapillary pattern.
Jing ZHANG ; Zhi-yong LIANG ; Tong-hua LIU
Chinese Journal of Pathology 2011;40(3):202-205
Adenocarcinoma
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Bronchiolo-Alveolar
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Papillary
;
metabolism
;
pathology
;
Cadherins
;
metabolism
;
Diagnosis, Differential
;
Genes, erbB-1
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Lymphatic Metastasis
;
Mucin-1
;
metabolism
;
Mutation
;
Neoplasm Invasiveness
;
beta Catenin
;
metabolism
7.Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Jinbo SHI ; Xiawei LI ; Yulian WU
Journal of Zhejiang University. Medical sciences 2021;50(3):375-382
To investigate whether chemotherapy could prolong the postoperative survival time in patients with early stages pancreatic ductal adenocarcinoma (PDAC). A total of 5280 stage ⅠA -ⅡB PDAC patients diagnosed from 2010 to 2015 were selected from surveillance,epidemiology,and end results (SEER) database. Propensity score matching (PSM) analysis was adopted to reduce the baseline differences between the groups. Univariate survival analysis was conducted with the Kaplan-Meier method. Multivariate survival analysis was performed with the Cox proportional hazards model. Univariate and multivariate survival analyses showed that age, differentiation, stage, chemotherapy were independent risk factors for the survival of PDAC patients. After PSM, it is found that adjuvant chemotherapy could prolong the median overall survival time (mOS) for stage ⅠB, ⅡA and ⅡB patients. However, for stage ⅠA patients, there were no significant differences in 3-year survival rate and mOS between patients with chemotherapy (=283) and without chemotherapy (=229) (57.4% vs 55.6%, vs all >0.05). Further analyses show that among 101 patients with well differentiated PDAC and 294 patients with moderately differentiated PDAC, there were no significant differences in survival rate and mOS between patients with and without chemotherapy (all >0.05). Among 117 patients with low-differentiated + undifferentiated PDAC, 3-year survival rate and mOS in patients with chemotherapy were significantly better than those without chemotherapy (48.5% vs 34.1%, vs all <0.05). Chemotherapy regimen used currently is not beneficial for patients with moderately and well differentiated stage ⅠA PDAC, but it is an independent prognostic factor for low-differentiated + undifferentiated PDAC patients.
Adenocarcinoma/pathology*
;
Carcinoma, Pancreatic Ductal/surgery*
;
Chemotherapy, Adjuvant
;
Humans
;
Neoplasm Staging
;
Pancreatic Neoplasms/drug therapy*
;
Prognosis
;
Propensity Score
8.S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer.
Jong Yul JUNG ; Sun Young RHA ; Joong Bae AHN ; Woo Ick YANG ; Sung Hoon NOH ; Hyun Cheol CHUNG ; Hei Cheul JEUNG
The Korean Journal of Internal Medicine 2008;23(1):37-41
S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. A 68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac axis and splenic hilum. His clinical stage was cT3N2H0P0M0. Considering his relatively poor performance (ECOG 2, severe weight loss) and advanced age, we started the patient on S-1 monotherapy at a dose of 35 mg/m2 bid for 4 consecutive weeks followed by a 2-week rest. Follow-up study after 4 treatment cycles revealed disappearance of the lymphadenopathy of the perigastric and celiac axis with diminished extension of the stomach mass. The patient had a partial response (PR) with a 72% tumor reduction, according to the Response Evaluation Criteria in Solid Tumors (RECIST). His performance status was improved to an ECOG 1 and he gained 7 kg. A curative (R0) resection was achieved with a radical total gastrectomy and D2 dissection. The pathological stage was pT3N2M0, stage IIIB. In conclusion, S-1 neoadjuvant chemotherapy aided in the treatment of gastric cancer in this patient.
Adenocarcinoma/*drug therapy/pathology/surgery
;
Aged
;
Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use
;
Drug Combinations
;
Gastrectomy
;
Humans
;
Male
;
*Neoadjuvant Therapy
;
Neoplasm Staging
;
Oxonic Acid/administration & dosage/*therapeutic use
;
Stomach Neoplasms/*drug therapy/pathology/surgery
;
Tegafur/administration & dosage/*therapeutic use
9.Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases.
Hua FANG ; Xing-yuan WANG ; Jin-wan WANG ; Hong-gang ZHANG ; Feng-yi FENG ; Yuan-kai SHI
Chinese Journal of Oncology 2009;31(3):220-222
OBJECTIVETo analyse the clinical characteristics and potential prognostic factors of colorectal cancer patients with liver metastases.
METHODSThe clinical and pathological data of 300 colorectal cancer patients with liver metastases were retrospectively reviewed and analyzed.
RESULTSThe median survival time of these patients was 19.0 months. The 1-, 2- and 5-year survival rates after liver metastases were 79.0%, 29.0% and 3.0%, respectively. Univariate analysis revealed that performance status (KPS), histological grading, primary tumor, N status, lymphatic and vascular invasion, stage at diagnosis, the number, size and distribution of liver metastases and other accompanied metastases were prognostic factors. Multivariate analysis showed that KPS, lymphatic and vascular invasion, the number and size of liver metastases were independent prognostic factors of colorectal cancer with liver metastases.
CONCLUSIONPerformance status, lymphatic and vascular invasion, the number and size of liver metastases are independent prognostic factors of colorectal cancer with liver metastases.
Adenocarcinoma ; drug therapy ; pathology ; secondary ; surgery ; Adenocarcinoma, Mucinous ; drug therapy ; pathology ; secondary ; surgery ; Adult ; Aged ; Aged, 80 and over ; Colonic Neoplasms ; drug therapy ; pathology ; surgery ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms ; drug therapy ; secondary ; surgery ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Neoplastic Cells, Circulating ; Proportional Hazards Models ; Rectal Neoplasms ; drug therapy ; pathology ; surgery ; Retrospective Studies ; Survival Rate ; Tumor Burden ; Young Adult
10.Simultaneous laparoscopic excision for the treatment of rectal carcinoma and the synchronous hepatic metastasis.
Kai-yun CHEN ; Guo-an XIANG ; Han-ning WANG ; Fang-liang XIAO
Chinese Journal of Oncology 2009;31(1):69-71
OBJECTIVETo evaluate the therapeutic efficacy of simultaneous laparoscopic excision for the treatment of rectal carcinoma and synchronous hepatic metastasis.
METHODSTotally 38 patients with rectal carcinoma and synchronous hepatic metastasis detected by CT scan were included in this study. Among them, 23 patients in the group A were treated with laparoscopic surgery, and the other 18 patients in the group B with traditional abdominal operation to resect the rectal tumor and hepatic metastasis simultaneously. All patients received postoperative chemotherapy.
RESULTSAll the patients were treated successfully with no postoperative death in both groups. The mean operative time was 350 +/- 45 min in group A versus 342 +/- 38 min in group B (P > 0.05). The mean blood loss was 275 +/- 96 ml in group A versus 590 +/- 85 ml in group B (P < 0.01), and the average hospital stay was 12 +/- 1.5 days in group A versus 16 +/- 2.5 days in group B (P < 0.05). Only one patient in group A received blood transfusion of 200 ml during operation, while the average blood transfusion in group B was 500 +/- 100 ml (P < 0.01). The follow-up duration was from 36 to 72 months with an average duration of 45.3 months. The 1-, 3- and 5-year survival rates were 82.6%, 43.5% and 8.6% in the group A, versus 77.8%, 38.9% and 0% in group B, respectively (P > 0.05).
CONCLUSIONSimultaneous laparoscopic excision of rectal carcinoma and synchronous hepatic metastasis is safe, effective and minimally invasive with a similar survival achieved by traditional open abdominal operation.
Adenocarcinoma ; drug therapy ; secondary ; surgery ; Aged ; Blood Loss, Surgical ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Laparoscopy ; methods ; Length of Stay ; Liver Neoplasms ; drug therapy ; secondary ; surgery ; Male ; Middle Aged ; Rectal Neoplasms ; drug therapy ; pathology ; surgery ; Survival Rate